HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Book sections

Targeting DOT1L for mixed-lineage rearranged leukemia

Abstract : Histone methyltransferases are potential therapeutic targets for human diseases, in particular cancer. Among them, DOT1L is a lysine histone methyltransferase (KHMT) that catalyzes the methylation of lysine 79 on histone 3. Structurally, its catalytic domain is distinguished by the presence of a seven-stranded β-sheet motif, common to arginine histone methyltransferases, making it a unique KHMT. In addition to this unicity, which makes it a very interesting therapeutic target from a medicinal chemistry point of view, DOT1L plays a major role in mixed-lineage rearranged leukemia, an important subset of acute leukemia with very poor overall survival rate. Here, after an introduction to DOT1L and its role in MLL-r leukemia, we discuss the development of DOT1L inhibitors for the treatment of MLL-r and the assays used to discover and evaluate the inhibitors.
Complete list of metadata

Contributor : Marie-Ange Garnier Connect in order to contact the contributor
Submitted on : Wednesday, November 24, 2021 - 10:58:04 PM
Last modification on : Thursday, April 7, 2022 - 1:58:35 PM
Long-term archiving on: : Friday, February 25, 2022 - 8:17:17 PM


Files produced by the author(s)




Corentin Bon, Yang Si, Paola B Arimondo. Targeting DOT1L for mixed-lineage rearranged leukemia. Histone Modifications in Therapy, 20, Elsevier, pp.81-99, 2020, Translational Epigenetics, 978-0-12-816422-8. ⟨10.1016/B978-0-12-816422-8.00005-2⟩. ⟨pasteur-03414682⟩



Record views


Files downloads